Zofran Lawsuit Plaintiffs Note Centers For Disease Control Are Tracking Birth Defect Reports

January 15, 2016 – – ZofranLegal.com reports on new news that Zofran birth defect lawsuit plaintiffs have become aware of concerning the Centers for Disease Control and birth defect tracking. Currently, the Zofran multidistrict litigation (number 2657) is moving forward with a growing number of complaints. The latest reports have seen lawsuit numbers surpass 200. Cases joining the MDL have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation, due to the fact that they share common allegations and were filed against the same defendant: pharmaceutical giant GlaxoSmithKline.

According to new information, the Centers for Disease Control have a system in place in 41 states across the country, though many see flaws within the process, the purpose of their birth defect tracking is to: monitor what defects may be increasing or decreasing as time goes on, identify potential causes of these defects, create greater public awareness of risk factors for defects in order to prevent defect increases, and assist parents who have children born with defects so that they are able to find proper help.

Plaintiffs involved in the Zofran birth defect lawsuits are now questioning if this tracking system may show what other studies have reported as well: that exposure to Zofran while developing in utero causes fetuses to be at greater risk for developing serious congenital birth defects.

Plaintiffs synonymously allege this is the case, and that specifically, Zofran exposure through their mothers has caused children to be born with cleft lip and palate, transposition of the greater vessels, atrial septal and ventricular septal defect, clubfoot, respiratory distress syndrome, and kidney defects. Multiple parents involved in the lawsuits have in fact tragically lost their children to these fatally severe defects, while others have had to watch as their infants endured multiple corrective surgeries.

Their complaints have been filed against GlaxoSmithKline, and address a very prominent issue: that their anti-nausea drug was never FDA-approved to treat pregnant women, or tested for safety on this consumer group. In 1991, the drug was specifically approved to treat patients suffering from nausea and vomiting after anesthesia, radiation, or chemotherapy. After this initial approval, however, GSK started to market the drug as a morning sickness treatment to Ob/Gyns and women across the nation. This is considered “off-label” marketing, which then led to a vast number of “off-label” prescriptions.

Plaintiffs state that GSK has been reckless and negligent by neglecting to inform the medical community and public of these findings, for choosing not to pursue human clinical trials, and for not seeking proper FDA approval for this new drug use before advertising it.

As involved plaintiffs anxiously await legal proceedings, the attorneys at Monheit Law are working diligently to attempt to help anyone else who may be affected. Mothers who were prescribed Zofran while pregnant and who subsequently gave birth to children with defects may be entitled to legal action and significant compensation. Monheit Law is offering these individuals free consultations should they wish to pursue justice.

To obtain additional information regarding Zofran birth defect lawsuits, or to ask questions, please contact Michael Monheit of Monheit Law by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60007302